Key Takeaways
- Quality earnings beat, one provision aside: Revenue grew 11% for the full year, above the 4–8% guided range, and contribution margin expanded 220 bps. A single ₹350 cr doubtful-debt provision masked 22% underlying EBITDA growth in Q4.
- The balance sheet is no longer the story: Gross debt fell $850 mn (40% from peak), net debt fell $400 mn (48%), and gearing improved from 4.6x to below 1.6x, all funded from internal cash.
- The mix shift is real and margin-accretive: Advanta grew 23%, SUPERFORM’s specialty share moved from 20% to 28%, and the innovation rate improved to 16%, together driving a structural lift in group contribution margin.
- Guidance is deliberately narrow: Only Q1 is guided (10–14% revenue growth, 14–18% EBITDA growth) because management sees the Middle East crisis, supply-chain disruption and cost inflation as too uncertain to call the full year.
- What to watch next quarter: Whether the Q1 guided growth actually lands, the pace of the SUPERFORM specialty mix shift toward the 60/40 target, and any board decision on the platform reorganization structure.
The Quarter in Detail: Growth, Provision & Quality
- Q4 top-line strength: Revenue grew 20% YoY, driven by strong volumes across Brazil, North America, Europe and Asia Pacific. Herbicides and fungicides led, while the insecticide portfolio began to recover, particularly Acephate-based brands in Brazil.
- The provision that reshaped optics: A conservative ₹350 cr expected credit loss provision, reflecting farm-level stress and distributor credit concerns, pushed reported EBITDA growth down to 13%. Excluding it, EBITDA growth would have been 22% and the margin ~22%.
- Full-year margin walk: Contribution margin improved ~250 bps to 31.5%, with all four platforms improving contribution margin in every single quarter versus the prior year. Supply-chain efficiencies, lower COGS and better capacity utilization did the work.
- Below-EBITDA cleanup: The four problematic line items (FX, exceptionals, net finance cost, JV/associates) were reduced by ₹1,300 cr, or 28%, driving PBT to nearly 4x and operational PATMI to over 2.5x.
- India: flat revenue, better business: Revenue was preserved despite ~₹150 cr of phased-out brands, a ₹100–200 cr monsoon hit in the strongest markets, and extreme price erosion. Contribution improved 19% and EBITDA improved 24% because the company scaled new brands and positioned Q4 inventory closer to consumption.
Ravishankar Cherukuri: "We preserved our revenue in the face of many headwinds. … Despite all of that stuff, we scaled up the brands that we focused on in a way that we ended up preserving our revenue while significantly improving our contribution by 19% and EBITDA by 24%."
Balance Sheet & Capital Structure
- Debt reduction delivered: Gross debt reduced by $850 mn (40% from the FY24 peak) and net debt by $400 mn (48% from peak) through disciplined cash management and internal accruals. Gearing improved from 4.6x to below 1.6x.
- Liquidity milestones cleared: A $500 mn loan due March 2026 was repaid entirely from internal cash. A $400 mn loan maturing September 2026 was extended by three years to March 2029. A $300 mn committed revolving credit facility was arranged as a cushion.
- Perpetual bonds redeemed: $400 mn of perpetual bonds were redeemed on the first call date in May 2025, again from internal cash accruals.
- Refinancing done at better pricing: The refinancing and additional lines arranged during the March crisis were obtained at a better price than when UPL was investment grade.
- Working capital is now tight: Cycle time ended at 57 days, which management believes is very difficult to maintain and that ~65 days is more realistic. No further working capital release is expected going forward because the cycle is already very tight.
- Currency translation warning: Fixed assets showed a notional ~₹4,000 cr increase solely because the balance-sheet closing rate moved from 88 to 94.5. In constant-currency dollar terms, fixed assets actually declined. Management urges analyzing the balance sheet in dollar terms to avoid misleading indicators.
Bikash Prasad: "So if we don't report it in probably properly and the right way to look at it in the constant currency and the dollars, it will be misleading you and it will not give you the right perception."
Platform Performance
| Platform | Revenue Trend | Key Driver |
|---|---|---|
| Advanta | ▲ 23% YoY | Volume +12%, price +6%, forex +5%; growth balanced across four continents and five crop segments. Now a top-10 global seed company. |
| UPL Corp | ▲ 11% YoY | Volume-led growth amid global uncertainty, with broad-based regional contribution. |
| India SAS | ▬ Flat | Revenue preserved despite brand phase-outs, monsoon impact and price erosion; contribution and EBITDA up sharply on mix. |
| SUPERFORM | ▬ Flat (1%) | Top line suppressed by falling input prices passed through in the CMO cost-plus model, but specialty share rose from 20% to 28%, lifting contribution margin 240 bps to 24.7%. |
- Advanta’s resilient growth model: Management prioritizes consistent growth over patchy performance, with a 10-year track record to back it. Supply-chain optimization (60%+ hybrid overlap across Asian countries) allows inventory built in lower-cost India to move across the region, managing cash flow efficiently.
- SUPERFORM’s structural shift: The Ag/Specialty mix is targeted to move from 72/28 to 60/40 in the next 48 months, with specialty chemicals growing at 20%+ and carrying 18–20% EBITDA margins versus 12–13% for agchem. The lubricant additive business tripled and capacity was expanded 3x.
- India’s deliberate channel reset: The company launched OpenAg® Partners for elite customers, began fine-tuning distribution to give greater skin in the game to the best partners, and took price moves in March when competitors waited until April.
Bhupen: "What is our core is rather than having patchy growth scenario, we look for resilient and consistent growth year after year, which you can see last 10 years track record of Advanta."
Innovation, NPP & the Pipeline
- Innovation rate improving: The share of products introduced in the last five years rose from 14% to 16% of total sales, with a target closer to 18% by end-FY27. More than 300 new products launched in FY26 generated over $160 mn in revenue, exceeding the ~$130 mn target.
- Crop protection pipeline: Current pipeline value is ~$4.4 bn at peak sales, with ~$1.5 bn to be actualized by FY30. At peak, ~80% is differentiated and sustainable, ~20% post-patent. There are 27 molecules in development, 5 new entrants since the last Capital Markets Day, and 17 new solution platforms.
- NPP growth ambition: The Natural Plant Protection portfolio is on track to reach close to $700 mn in FY27, with a ~12% CAGR expected through FY31 and confidence in the ~$1 bn target by FY31. Ten new technologies are in the NPP development pipeline.
- Nuvita® launch: Successfully launched in Argentina, Brazil and Thailand as a technology allowing plants to use fertilizer and nutrients more efficiently, positioned as an upside opportunity in a high-fertilizer-price environment.
- Regulatory engine: Over 2,500 dossiers submitted and ~2,700 approvals obtained globally.
Reorganization & Value Unlocking
- Platform separation announced: The scheme involves separating platforms, with SUPERFORM staying with UPL Ltd as the manufacturing platform and Advanta and UPL Corp becoming distinct entities.
- Management’s conviction: The structure has been discussed and reviewed by advisors, with at least 10 different structures evaluated before arriving at the current one. Management believes these companies will grow at least 3x–4x the other players in the space.
- Feedback loop in progress: Management has been talking to analysts, FIIs and DIIs over the last two months post-announcement, maintaining a detailed tracker of feedback. Unfiltered feedback will be presented to the board in a month or two, with a decision on next steps to follow.
Jaidev Shroff: "These companies are going to grow at least 3x-4x the other players you've ever seen in this space growing."
Market Environment & Risk Management
- Market has stabilized, not rebounded: Management’s view is that the downcycle hit bottom and began to stabilize through 2025 and FY26, with opportunities emerging even though the market has not rebounded. Market volatility is now assumed to be the norm.
- Iran/Strait of Hormuz mitigation: Mitigation measures include disciplined sourcing, agile supply-chain management and pricing actions to cover higher costs. The market reaction has been uneven, and the company is focused on what it can control.
- Pricing discipline: The company takes an extremely conservative approach, pricing based on replacement cost with no speculation and no long-term commitments. All sales are committed and not renegotiable, so cost increases are passed on.
- Brazil market shift: The whole market has moved to just-in-time buying, with distribution purchasing closer to season and not taking advanced orders like 2–3 years ago. Management declined to provide specific order-book numbers when asked.
- Credit risk management in LATAM: Concentration of credit is being managed; in Argentina, only medium-to-high-margin products are sold, and the Origeo JV with Bunge uses grain as a tool to manage credit risk with growers.
Raj Tiwari: "We don't punt, we don't believe in speculations. And therefore, we should be able to pass on whatever the cost increase has been there."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q1 FY27 revenue growth | 10% to 14% YoY; positive price impact across most platforms; FX positive 7–9% | Q1 FY27 |
| Q1 FY27 EBITDA growth | 14% to18% YoY; 6–7% currency impact at EBITDA level | Q1 FY27 |
| Innovation rate | Closer to 18% (products introduced in last 5 years) | End-FY27 |
| NPP revenue | Close to $700 mn | FY27 |
| SUPERFORM Ag/Specialty mix | Shift from 72/28 to 60/40 | Next 48 months |
| SUPERFORM specialty EBITDA margin | ~20% for the business at that mix | Next 48 months |
| Group gearing target | 1.2x to1.5x; below 1.5x, likely to stay at that level | Medium-term |
| FY27 capex | $300–350 mn (~$325 mn), driven by specialty chemicals and backward integration | FY27 |
| FY27 ETR | ~20–22% | FY27 |
| Net debt/EBITDA | Comfortably within or less than 1.5x | Ongoing |
| Working capital cycle time | ~65 days going forward | Ongoing |
| Crop protection pipeline actualization | ~$1.5 bn of ~$4.4 bn peak-sales pipeline | By FY30 |
| NPP revenue target | Close to $1 bn | By FY31 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹52,000 cr (FY26), +11% YoY, largely volume-led |
| Revenue growth | +18% YoY, over a stellar Q4 FY25 base |
| EBITDA | +13% YoY |
| EBITDA margin | 19.9%; would have been ~22% excluding a ₹350 cr provision for doubtful debt (per an analyst's math) |
| PATMI (net income) | +18% YoY |
| Contribution margin | Improved ~50 bps YoY |
| SG&A | +27% YoY, includes ₹350 cr provision for doubtful debt |
| Gross debt | $2.3 bn (FY26), reduced by $850 mn in FY26; down 40% from $3.8 bn in FY24 |
| Net debt | $1.6 bn (FY26), reduced by $400 mn in FY26; down 48% from $3.1 bn in FY24 |
| Gearing ratio (Net debt/EBITDA) | Below 1.6x, better than guidance; FY25: 2.1x, FY24: 4.6x |
| Return on Equity | Almost doubled vs last year |
| Working capital cycle time | 57 days, marginally up 4 days YoY; management comfortable at ~65 days |
| Capex | $261 mn (FY26), vs guidance of ~$250 mn |
| UPL Corp revenue growth | +11% YoY (FY26) |
| Advanta revenue growth | +23% YoY (FY26) |
| India SAS revenue | Flat (FY26), due to monsoon effect |
| SUPERFORM revenue | ₹10,298 cr (FY26), +1% YoY; specialty chemicals share moved from 20% to 28% |
| Innovation rate | 16% (FY26), up from 14% in FY25; products introduced within last 5 years |
| Revenue from new product launches | Over $160 mn (FY26), ~4% of total revenue; exceeded target of ~$130 mn |
| NPP revenue target | Close to $700 mn expected in FY27; confident of ~$1 bn by FY31 |
| Q1 FY27 revenue growth guidance | 10% to 14% YoY |
| Q1 FY27 EBITDA growth guidance | 14% to 18% YoY |
| FY27 capex guidance | $300–350 mn |
| FY27 effective tax rate guidance | 20–22% |